Amicus Therapeutics (NASDAQ:FOLD)
is shaping up as a positive example of what happens when patience is
matched with good underlying science. There have definitely been some
large potholes along the way, including accusations that the company was
playing fast and loose with post-hoc analysis, but the underlying idea
that Fabry disease is a heterogenous disease and that Galafold
(migalastat) can help some, but not all, of those patients as a
monotherapy seems to have ultimately won the day.
Although these
shares don't look particularly cheap today, there are still
value-creating opportunities in front of the company. Actual approval
should de-risk the valuation and final pricing of the drug could be a
value-driver as well. Amicus's pipeline behind Galafold monotherapy
isn't particularly mature, but the opportunities to leverage Galafold
into combination therapies and advance additional rare disease
treatments into the clinic are potential value drivers down the road.
Read more here:
Amicus Fairly Rewarded For Substantial Progress
No comments:
Post a Comment